Home・Aandelen Lijst・Johnson and Johnson

Johnson and Johnson

Gesloten

SectorGezondheidszorg

259.29 0.86

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

256.6

Max

259.5

Belangrijke statistieken
By Trading Economics
Inkomsten	299M 5.5B
Verkoop	1.2B 25B
K/W Sectorgemiddelde	29.548 68.51
EPS	2.9
Dividendrendement	2.04
Winstmarge	21.865
Werknemers	138,200
EBITDA	-1.1B 7.2B

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+8.39% upside

Dividenden
By Acuity
Dividendrendement Sectorgemiddelde	2.04% 2.29%
Volgende Winsten	13 okt 2026
Volgende dividenddatum	8 sep 2026
Volgende Ex Dividend datum	25 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-5.5B 613B
Vorige openingsprijs	258.43
Vorige sluitingsprijs	259.29

Nieuwssentiment

By Acuity

38%

62%

96 / 340 Rangschikking in Healthcare

Johnson and Johnson Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 aug 2026, 00:02 UTC

Johnson & Johnson shares declined in after-market trading, retracing from a brief recovery and currently positioned at the midpoint of their one-month trading range.

7 aug 2026, 23:41 UTC

Johnson & Johnson shares are lower in after-market trading, experiencing notable volatility with no specific news identified to explain the movement.

6 aug 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-market hours, following a session within its one-month trading range. No specific news was identified for the move.

5 aug 2026, 23:51 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting routine performance within their one-month trading range amid broader cautious market sentiment.

4 aug 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting routine performance and stability amid broader market conditions.

3 aug 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-market trading, supported by stronger-than-expected manufacturing PMI data for July that signals sector growth.

1 aug 2026, 00:01 UTC

Johnson & Johnson shares gained in after-market trading, reflecting a cumulative return of 0.35% since Friday's close, despite no specific news driving the movement.

31 jul 2026, 23:01 UTC

Johnson & Johnson shares are higher in after-market trading, showing notable strength amid mixed performance in U.S. markets with no specific news identified.

30 jul 2026, 18:22 UTC

News

Event

Johnson & Johnson shares are lower amid concerns over a $1 billion acquisition of Firefly Bio and a partnership with Sail Biomedicines, impacting future earnings.

29 jul 2026, 21:41 UTC

News

Johnson & Johnson lowered its fiscal year 2026 adjusted EPS guidance to $10.86 to $11.01, contributing to a decline in after-market trading.

28 jul 2026, 23:31 UTC

Johnson & Johnson shares are higher in after-market trading, remaining above their 20-day moving average after six consecutive daily gains.

27 jul 2026, 23:31 UTC

News

Social Media

Johnson & Johnson shares are higher in after-market trading following a proposed $5.5 billion settlement for ovarian talc litigation involving about 76,000 claims.

24 jul 2026, 23:26 UTC

Johnson & Johnson shares declined in after-market trading, continuing a downward trend since Friday's close, despite the broader market's stability amid bond market concerns.

23 jul 2026, 10:06 UTC

Event

Johnson & Johnson's OTTAVA™ Robotic Surgical System received FDA authorization. Shares are lower in pre-market trading amid broader market declines.

22 jul 2026, 23:36 UTC

Event

Johnson & Johnson shares are higher in after-market trading following FDA authorization of the OTTAVA™ Robotic Surgical System, the first table-integrated soft tissue robotic system.

21 jul 2026, 23:11 UTC

Shares of Johnson & Johnson are higher in after-market trading, with no specific news identified. The stock remains below its 20-day moving average.

20 jul 2026, 19:26 UTC

Social Media

News

Johnson & Johnson shares are lower today, continuing a decline since Friday. The company targets $101 billion in revenue amid bearish technical trends.

Peer Vergelijking

Prijswijziging

Johnson and Johnson Prognose

Koersdoel

By TipRanks

8.39% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 281 USD 8.39%

Hoogste 305 USD

Laagste 255 USD

Gebaseerd op 17 Wall Street-analisten die 12-maands prijsdoelen bieden voor Johnson and Johnson - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

17 ratings

Buy

Hold

Sell

Gebaseerd op 17 analisten die aandelenratings hebben gegeven aan Johnson and Johnson - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

96 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.